Although serum selenium was similar overall in CLL patients compared with levels in the controls, levels were significantly lower in Rai stages 3 to 4 compared to Rai stages 0 to 2 (0.079 Ϯ 0.011 v 0.108 Ϯ 0.006 g/mL; P ϭ .0390). In addition, serum selenium correlated negatively (P Ͻ .05) with the lymphocyte count in patients with more than 20 ϫ 10 9 /L lymphocytes. Therefore, serum selenium seemed to be related to the extent of the disease. However, we emphasized that we could not determine whether differences in selenium levels were responsible for or caused by tumor proliferation. In a final study, serum selenium levels were measured before, during, and after high-dose induction chemotherapy in 70 patients with acute myelogenous leukemia (AML). 5 Pretreatment serum selenium levels were lower in patients than in controls (0.082 Ϯ 0.033 v 0.097 Ϯ 0.035 g/mL; P Ͻ .01) and correlated inversely with the absolute peripheral blast cell count (P Ͻ .001) and other measures of the tumor burden. After 7 days of chemotherapy, selenium increased significantly in proportion to the initial tumor burden (P Ͻ .01). Thereafter, serum selenium levels remained normal in patients entering a complete remission, whereas levels gradually decreased to baseline values in patients who experienced treatment failure. These data do not lend support to the hypothesis that a low selenium status enhances the risk of developing AML, but indicate that serum selenium levels in patients with AML are mostly dependent on tumor activity.
In view of the close relationship with tumor burden and the rapid modifications induced by chemotherapy, a mechanism of selenium sequestration by tumor cells is possible. Some evidence that certain tumors can accumulate selenium has been reported. 6 In their article, Last et al indicate that performance status was the only clinical variable correlating with selenium concentration, but they do not show any data on such associations with stage, serum lactate dehydrogenase, International Prognostic Index, tumor masses, or other factors. In addition, follow-up measurements during chemotherapy would have been most useful.
Contrary to the conclusions of the authors, we believe that until all these aspects of selenium metabolism in lymphoma patients are clearly sorted out, incorporation of selenium supplementation into an overall therapeutic strategy is not warranted. It could even have some unforeseen deleterious effects on outcome.
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